Matthew Herper, STAT

Matthew Herper

STAT

New York, NY, United States

Contact Matthew

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • Unknown
Past:
  • STAT
  • CNBC
  • Forbes

Past articles by Matthew:

With a potent new medicine, Merck marks a return to cardiology

A new medicine represents a dramatic advance for patients with a rare condition called pulmonary arterial hypertension — and a return to heart disease for Merck, which long had a legendary presence in cardiology. → Read More

After its drug was shown to prevent heart attacks, what’s next for Esperion?

Promoting a cardiovascular drug requires a huge marketing lift, and Esperion has a market capitalization of just $500 million. → Read More

Heart repair, risky genes, and AI: the buzz from a giant cardiovascular conference

An implantable heart clip from Abbott Laboratories led to reductions in hospitalization and death compared to standard care in a study enrolling severely ill patients, an endorsement of a device whose benefits have long been divisive. → Read More

New weight loss drugs are changing the narrative on obesity, with a push from pharma

A new generation of obesity drugs is transforming patients’ lives, dividing medical experts, and spurring the biggest business battle in years. And pharma is steering the discussion. → Read More

Esperion Therapeutics’ statin alternative reduces heart attack risk. Is that enough to save the company?

Results for Nexletol, a cholesterol-lowering pill, suggest it will be useful for people at high risk for heart attacks who are unable or unwilling to take statins. → Read More

Eli Lilly cuts prices for some insulin products, but some are wary

Eli Lilly, one of the largest makers of insulin, said it would make dramatic cuts to the prices of several of its older insulin products in an effort to lower costs for consumers whose insulin is not fully paid for by insurance. → Read More

One type of artificial sweetener may increase heart attack risk, preliminary study says

The sweetener erythritol, which is becoming increasingly popular in snack bars and low-sugar ice cream substitutes, may increase the risk of heart attacks and strokes, according to a new study. → Read More

Christi Shaw, leader of Gilead’s cancer cell therapy unit, to depart

Christi Shaw, the CEO of Gilead’s Kite Pharmaceuticals cell therapy unit, is leaving the company, Gilead said Friday in a statement. → Read More

With $520 million in hand, two entrepreneurs try to upend the biotech funding model

With $520 million in hand, two entrepreneurs are trying to upend the biotech funding model with Curie.Bio. → Read More

In another pharma shakeup, Sanofi loses top executive known for overhauling R&D

Sanofi head of R&D John Reed is leaving the pharmaceutical giant to pursue a new opportunity, the company announced Monday. → Read More

Bayer, facing investor ire, appoints an outsider CEO

Bayer named former Roche executive Bill Anderson as its new CEO, a decision that follows escalating pressure from shareholders. → Read More

New antidepressant study provides hints to Verily’s future

A new antidepressant study may hold clues about the future direction of Verily, the high-profile Alphabet spinout. → Read More

FDA advisers recommend updating Covid vaccines

Advisers to the FDA voted Thursday to back a plan whereby all Covid vaccines would move to the formulation used for the updated boosters, a step toward the goal of creating a single annual Covid shot for most Americans. → Read More

FDA scientists propose an annual Covid shot matched to current strains

Scientists at the FDA propose making Covid vaccinations a regular, once-a-year shot that is updated to match current strains of the SARS-CoV-2 virus. → Read More

Verily leans into Onduo as it looks to enter the lucrative world of running medical research

Verily plans to lean on its chronic disease care spinout Onduo as it looks to build a door into the lucrative world of running research. → Read More

Moderna says RSV vaccine worked, setting stage for competition with GSK and Pfizer

Moderna’s vaccine against the respiratory syncytial virus, or RSV, reduced the rate of lower respiratory disease in people over 60 in a Phase 3 trial, the company said Tuesday. → Read More

Virtual Event: "JPM Recap, Live!" 2023

Relive the return to an in-person J.P. Morgan Healthcare Conference with the STAT reporters who attended. → Read More

As Ginkgo stock sinks, CEO Jason Kelly tries to win over drugmakers in San Francisco

Ginkgo, a company that said its engineered cells could help make almost anything, is trying to drum up business. → Read More

Top Verily executives depart amid leadership shakeup and layoffs

Verily announced a major reorganization and layoffs Wednesday. The company told STAT executives Jessica Mega and Vivian Lee have left the Alphabet spinout. → Read More

Illumina, the DNA sequencing giant, gives Wall Street bad news

Illumina said its consolidated earnings per share would be in the range of $1.25, dramatically below the expected $2.99 per share. → Read More